We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+22.5%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$102M
AUM Growth
+$21.8M
Cap. Flow
+$7.13M
Cap. Flow %
7.01%
Top 10 Hldgs %
56.24%
Holding
49
New
13
Increased
10
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.25M
2
ACHC icon
Acadia Healthcare
ACHC
+$5.17M
3
ANAB icon
AnaptysBio
ANAB
+$3.42M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$3.33M
5
EXAS
Exact Sciences
EXAS
+$3.18M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$3.57M
2
NTRA icon
Natera
NTRA
+$2.51M
3
KALA icon
KALA BIO
KALA
+$2.13M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$1.94M
5
PFE icon
Pfizer
PFE
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 90.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDMN
26
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.44M 1.42%
361,517
+162,370
+82% +$634K
ECYT
27
DELISTED
Endocyte, Inc. Common Stock
ECYT
$1.42M 1.4%
103,159
+11,724
+13% +$139K
RGNX icon
28
Regenxbio
RGNX
$708M
$1.2M 1.18%
16,692
+684
+4% +$32.7K
VRCA icon
29
Verrica Pharmaceuticals
VRCA
$87.3M
$1.18M 1.16%
+6,000
New +$1.18M
XLRN
30
DELISTED
Acceleron Pharma
XLRN
$1.09M 1.08%
+22,558
New +$822K
DRRX
31
DELISTED
DURECT Corp
DRRX
$1.07M 1.06%
68,845
-6,432
-9% -$132K
STIM icon
32
Neuronetics
STIM
$166M
$958K 0.94%
+36,000
New +$979K
NCNA
33
NuCana
NCNA
$6.12M
$910K 0.89%
10
+2
+25% +$246K
SENS icon
34
Senseonics Holdings Inc
SENS
$366M
$595K 0.59%
+7,237
New +$519K
IMMU
35
DELISTED
Immunomedics Inc
IMMU
$466K 0.46%
+19,695
New +$396K
SNNA
36
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$372K 0.37%
+24,516
New +$416K
BSX icon
37
Boston Scientific
BSX
$71.5B
– –
-68,270
Closed -$1.86M
INGN icon
38
Inogen
INGN
$164M
– –
-12,471
Closed -$1.53M
KALA icon
39
KALA BIO
KALA
$14.5M
– –
-54
Closed -$2.13M
PBYI icon
40
Puma Biotechnology
PBYI
$454M
– –
-18,057
Closed -$1.23M
PEN icon
41
Penumbra
PEN
$12.8B
– –
-10,279
Closed -$1.19M
PFE icon
42
Pfizer
PFE
$153B
– –
-56,117
Closed -$1.89M
SNDX icon
43
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-135,974
Closed -$1.94M
TCMD icon
44
Tactile Systems Technology
TCMD
$665M
– –
-42,460
Closed -$1.35M
NVRO
45
DELISTED
NEVRO CORP.
NVRO
– –
-13,087
Closed -$1.13M
MTEM
46
DELISTED
Molecular Templates, Inc.
MTEM
– –
-113
Closed -$14K
TVTY
47
DELISTED
Tivity Health, Inc. Common Stock
TVTY
– –
-24,601
Closed -$975K
ARRY
48
DELISTED
Array Biopharma Inc
ARRY
– –
-81,649
Closed -$1.33M
LJPC
49
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-55,864
Closed -$1.66M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Asymmetry Capital Management held 49 positions worth $102M, up 27% from $79.9M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Asymmetry Capital Management deployed $7.13M of net new capital in Q2 2018, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 53,208 shares worth $9.04M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $3.57M trimmed.

  • Asymmetry Capital Management's largest Q2 2018 buy was Vertex Pharmaceuticals: 53,208 shares worth $9.04M.
  • Asymmetry Capital Management added most to Exact Sciences in Q2 2018, an estimated $3.18M increase.
  • Asymmetry Capital Management's biggest Q2 2018 reduction was PTC Therapeutics, cutting an estimated $3.57M.
  • Asymmetry Capital Management fully exited KALA BIO in Q2 2018, selling an estimated $2.13M.
  • Asymmetry Capital Management's ten largest holdings make up 56% of its $102M portfolio in Q2 2018.
  • Asymmetry Capital Management opened 13 new positions and closed 13 in Q2 2018.
  • Asymmetry Capital Management's portfolio value rose 27% quarter-over-quarter to $102M.

Based on Asymmetry Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.